RM

Rishabh Mandloi

Active Director Director DIN 08611047
DIN 08611047 First appointment Jul 2020 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2020
Shareholding value •••• Premium profile

About Rishabh Mandloi

Data last updated:

Rishabh Mandloi is a Director at Eamon Drugs Private Limited (since 2020). The company operates in Pharma. Eamon Drugs Private Limited reported revenue of ₹15.64 Cr (FY 2025).

DIN 08611047
Primary Designation Director
Industry Pharma
First Appointment 14 Jul 2020
Oldest Company Age 41 yrs
Largest company Eamon Drugs Private Limited · ₹15.64 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Eamon Drugs Private Limited U24114MP1985PTC003021
Director14 Jul 20201985₹15.64 Cr (FY 2025)Active

Board colleagues of Rishabh Mandloi

Directorship timeline

Open interactive timeline →
Eamon Drugs Private Limited
Premium access

Shareholding and investment profile for Rishabh Mandloi

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rishabh Mandloi

Rishabh Mandloi currently holds 1 directorship: Eamon Drugs Private Limited (Director, since 14 Jul 2020, revenue ₹15.64 Cr (FY 2025)).

Rishabh Mandloi was first appointed on 14 Jul 2020 as Director at Eamon Drugs Private Limited.

The current boards of Rishabh Mandloi's companies include Mahendra Kumar Mandloi (Eamon Drugs Private Limited), Udit Sodani (Eamon Drugs Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available